In insulin-dependent diabetes with hyperfiltration, octreotide lowered mean GFR to 136 (range 91 to 158) versus placebo 157 (138 to 184) mL/min per 1.73 m2.
In plain wordsIn insulin-dependent diabetes, octreotide significantly reduced glomerular filtration rate compared with placebo after 12 weeks.
- Peptide
- Octreotide
- Outcome
- DecreaseGlomerular filtration rate
- Study
n = 11
- Comparator
- Placebo
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- 300 micrograms/24 h · continuous subcutaneous infusion · 12 weeksAs given in this study (human).
Measurements
- Mean glomerular filtration rate
- 136 mL/min per 1.73 m2
- octreotide group, 12 weeks
- Glomerular filtration rate range
- 91 to 158 mL/min per 1.73 m2
- octreotide group, 12 weeks
- Mean glomerular filtration rate
- 157 mL/min per 1.73 m2
- placebo group, 12 weeks
- Glomerular filtration rate range
- 138 to 184 mL/min per 1.73 m2
- placebo group, 12 weeks
Source sentences
However, after 12 weeks of treatment, the mean glomerular filtration rate was significantly lower in the octreotide group (136 mL/min per 1.73 m2; range, 91 to 158 mL/min per 1.73 m2) than in the placebo group (157 mL/min per 1.73 m2; range, 138 to 184 mL/min per 1.73 m2).
2 context sentences(design, population, supporting numbers)
To determine whether treatment with a somatostatin analogue can reduce kidney hyperfiltration and hypertrophy in insulin-dependent diabetes mellitus, we studied 11 patients with insulin-dependent diabetes mellitus and glomerular hyperfiltration.
The patients were assigned randomly to receive continuous subcutaneous infusion of either octreotide, 300 micrograms/24 h (five patients) or placebo (six patients) for 12 weeks.